Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis

Could Early Tranexamic Acid Safely Serve as an Anti-inflammatory Treatment for Patients With Sepsis? A Randomized Double Blind Controlled Trial

In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.

A written informed consent will be taken from the patients or their relatives.Patients will be assigned randomly to two groups (40 subjects each) with qSOFA ≥2.

In (Group T) administer 1 gram of tranexamic acid (TXA) in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of tranexamic acid (TXA) IV over 8 hours in 0.9% normal saline for the first 3 days. In (Group C) administer the same volume (100 ml normal saline)and same duration (first three days)for controlled patients.

Inclusion Criteria:

• Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2
• & needed ICU admission.

Exclusion Criteria:

• Chronic renal failure
• Liver cirrhosis
• Bleeding disorders or current anticoagulant therapy
• Pregnancy or breastfeeding
• Impaired color vision
• Severe vascular ischemia, history of venous thrombosis & pulmonary embolism
• Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission
• Allergy to tranexamic acid (TXA)